Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects

URN to cite this document:: urn:nbn:de:bvb:355-epub-377953
DOI to cite this document:: 10.5283/epub.37795

Munker, Stefan ; Gerken, Michael ; Fest, Petra ; Ott, Claudia ; Schnoy, Elisabeth ; Fichtner-Feigl, Stefan ; Wiggermann, Philipp ; Vogelhuber, Martin ; Herr, Wolfgang ; Stroszczynski, Christian ; Schlitt, Hans Jürgen ; Evert, Matthias ; Reng, Michael ; Klinkhammer-Schalke, Monika ; Teufel, Andreas

License: Creative Commons Attribution 4.0
PDF
(640kB)

Date of publication of this fulltext: 27 Sep 2018 17:16

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background: 5-Fluorouracil (5FU), Folinic acid (FA), and Oxaliplatin (FOLFOX) or 5FU, FA, and Irinotecan (FOLFIRI) are standard regimens for palliative chemotherapy of metastatic colon cancer. Since data showing the influence of dose reduction in palliative treatment are rare, the objective of this single center, retrospective study was to further characterize the influence of dose reduction on ...